Companies › Eli Lilly › Revenue
Eli Lilly revenue, 2008–2025
Eli Lilly reported revenue of $65.2 billion for the fiscal year ended Dec. 31, 2025, up 44.7% from $45.0 billion the year before, according to its Form 10-K.
Fiscal years labeled by the year in which they ended. Bars drawn from the table below.
Eli Lilly revenue by fiscal year
| Fiscal year ended | Revenue | Change | Filing |
|---|---|---|---|
| Dec. 31, 2025 | $65.2B | +44.7% | 10-K (2026) ↗ |
| Dec. 31, 2024 | $45.0B | +32.0% | 10-K (2026) ↗ |
| Dec. 31, 2023 | $34.1B | +19.6% | 10-K (2026) ↗ |
| Dec. 31, 2022 | $28.5B | +0.8% | 10-K (2025) ↗ |
| Dec. 31, 2021 | $28.3B | +15.4% | 10-K (2024) ↗ |
| Dec. 31, 2020 | $24.5B | +9.9% | 10-K (2023) ↗ |
| Dec. 31, 2019 | $22.3B | +3.8% | 10-K (2022) ↗ |
| Dec. 31, 2018 | $21.5B | +7.6% | 10-K (2021) ↗ |
| Dec. 31, 2017 | $20.0B | −5.9% | 10-K (2020) ↗ |
| Dec. 31, 2016 | $21.2B | +6.3% | 10-K (2019) ↗ |
| Dec. 31, 2015 | $20.0B | +1.7% | 10-K (2018) ↗ |
| Dec. 31, 2014 | $19.6B | −15.1% | 10-K (2017) ↗ |
| Dec. 31, 2013 | $23.1B | +2.3% | 10-K (2016) ↗ |
| Dec. 31, 2012 | $22.6B | −6.9% | 10-K (2015) ↗ |
| Dec. 31, 2011 | $24.3B | +5.2% | 10-K (2014) ↗ |
| Dec. 31, 2010 | $23.1B | +5.7% | 10-K (2013) ↗ |
| Dec. 31, 2009 | $21.8B | +7.2% | 10-K (2012) ↗ |
| Dec. 31, 2008 | $20.4B | — | 10-K (2011) ↗ |
Other Eli Lilly financials
Net incomeDiluted EPSR&D expenseOperating cash flowDividends per shareDiluted sharesTotal assetsCash and equivalentsStockholders' equity Quarterly results and next earnings date Eli Lilly company hub
FAQ
Q What was Eli Lilly's revenue in its latest fiscal year?
A Eli Lilly reported revenue of $65.2 billion for the fiscal year ended Dec. 31, 2025, up 44.7% from $45.0 billion the year before, according to its Form 10-K.
Q What is Eli Lilly's highest annual revenue on record here?
A $65.2 billion, in the fiscal year ended Dec. 31, 2025, among the fiscal years 2008–2025 reported in its 10-K XBRL data.
Q Where does this revenue data come from?
A From Eli Lilly's annual reports on Form 10-K, as tagged in XBRL and published by the SEC (company facts). Total revenue as reported in the 10-K income statement (net of interest expense for banks).
Source: Eli Lilly's annual reports on Form 10-K via SEC XBRL company facts, updated Oct. 15, 2026. Total revenue as reported in the 10-K income statement (net of interest expense for banks). For each year the most recent 10-K that reports it is used, so a figure a company later restated shows the restated value; the filing link shows which report it came from. Change is our arithmetic. Financial data, not investment advice.